eClinical Technology and Industy News


Excerpt from the Press Release:

SAN DIEGO, June 14, 2022 /PRNewswire/ — HUYABIO International today announced that the first three patients had been dosed in an ongoing Phase 2 study of HUYABIO’s novel drug for pharmacological cardioversion of atrial fibrillation (AF).

Dr. Mireille Gillings, President, CEO & Executive Chair, said, “We are excited to proceed with dosing AF patients in our Phase 2 trial of HBI-3000. AF is a growing global problem and HUYABIO’s drug is well-positioned to provide a new pharmacological treatment for patients, many of whom would otherwise get electrically cardioverted which can be both stressful and painful.”

The study is evaluating pharmacological cardioversion of acute AF. Cardioversion aims to restore a normal heart rate and rhythm in AF patients and is often done by high energy electrical shock. The Phase 2 trial HBI-3000-402 is a two-stage, serial cohort dose escalation and expansion study of a single intravenous infusion of HBI-3000 in patients with AF between 2 and 72 hours.

Denis Roy, MD, Montreal Heart Institute and Chief Investigator of the trial, said, “Demonstrating efficacy of HBI-3000 in this trial is an important step towards development of a new therapeutic option to AF patients.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary Data Management

Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?